Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Metso to buy Valmet’s Flowrox hose and progressive cavity pump business

Metso to buy Valmet’s Flowrox hose and progressive cavity pump business

ReutersReuters2026/08/24 06:04
  • Metso agreed to buy Valmet’s peristaltic hose pump and progressive cavity pump technologies, including related spare parts and service capabilities.
  • Deal expands Metso’s slurry-handling offering for mining and industrial applications, adding a growing installed base with stable aftermarket revenue.
  • Transaction is expected to close on Oct. 1, 2026; financial terms were not disclosed.
  • Products, currently sold under the Flowrox brand, will be rebranded under Metso; production will move to Lappeenranta, Finland.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metso Oyj published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

As traditional automakers cut back on their loss-making electric vehicle businesses, Tesla (TSLA.US) has regained more than half of the US electric vehicle market share.

智通财经2026/09/14 01:06
The US EV landscape after subsidy cuts: traditional automakers cut and halt production, Tesla (TSLA.US) regains the majority share with Model Y

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas